HA-Gd2O3-NPs, as a drug carrier, specifically targets EGFR mutant NSCLC cells and efficiently releases loaded drugs, which provides a new method for EGFR mutant lung cancer patients to overcome the resistance of EGFR-TKI. Here, EGFR is linked to lung cancer.